Skip to content

Surgical Trial In Traumatic intraCerebral Haemorrhage

Surgical Trial In Traumatic intraCerebral Haemorrhage: an international multi-centre pragmatic randomised parallel group trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN19321911
Enrollment
840
Registered
2009-03-27
Start date
2009-09-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Traumatic intracerebral haemorrhage and contusion Injury, Occupational Diseases, Poisoning Intracerebral haemorrhage

Interventions

Early surgery vs initial conservative treatment

Sponsors

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Both males and females, adults aged 14 or over 2. Evidence of a traumatic intracerebral haemorrhage (TICH) on computed tomography (CT) with a single volume of attenuation significantly raised above that of the background white and grey matter that is in total greater than 10 ml calculated by width times height times length in cm divided by 2 3. Within 24 hours of head injury 4. Clinical equipoise: only patients for whom the responsible neurosurgeon is uncertain about the benefits of either treatment are eligible

Exclusion criteria

Exclusion criteria: 1. A significant surface haematoma (epidural haematoma [EDH] or subdural haematoma [SDH]) requiring surgery (The indications for intervention for these patients are already very well defined) 2. More than two separate haematomas fulfilling inclusion criteria 3. If surgery can not be performed within 36 hours of injury or 12 hours of randomisation (whichever is the shorter) 4. Severe pre-existing physical or mental disability or severe co-morbidity which might lead to a poor outcome even if the patient made a full recovery from the head injury (Examples would be a high level of dependence before the injury or severe irreversible associated injury such as complete spinal cord injury) 5. Permanent residence outside a study country preventing follow up 6. Patient and/or relative has a strong preference for one treatment modality

Design outcomes

Primary

MeasureTime frame
Unfavourable outcome will be death or severe disability which will be defined using a prognosis based 8 point Glasgow Outcome Scale. Total duration of follow-up: 6 months

Secondary

MeasureTime frame
The following will be assessed at 6 and 12 months: 1. Rankin scale 2. Euroqol EQ-5D 3. Mortality 4. Survival 5. Major Adverse Events (death, pulmonary embolism or deep vein thrombosis, infection, rehaemorrhage) 6. Quality-adjusted life-years (QALYs) 7. Total health care costs 8. Social costs

Countries

Czech Republic, Egypt, Germany, Greece, India, Italy, Latvia, Lithuania, Macedonia, Poland, Russian Federation, Spain, United Kingdom, United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 25, 2026